Botanee's first self-developed medical aesthetic injectable approved, opening second growth curve
First self-developed medical aesthetic injectable approved Botanee's BTN001 injectable sodium hyaluronate received NMPA approval as its first self-developed Class III medical device. Sold only in medical institutions, it can open a new revenue stream beyond skincare, giving the stock a fresh growth story.
This is the period's biggest new product event and the main reason the stock has a new growth narrative.
First-half profit grew faster than revenue First-half net profit rose 18.3% to 292 million yuan while revenue grew 9.3%, and adjusted profit jumped 34.9%. Gross margin was high at 74.6% and selling costs fell, showing the core business is getting more efficient.
Profit growth and margin improvement are the fundamental support under the stock price.
Buybacks and first interim dividend return cash Botanee repurchased about 3.7 million shares for roughly 120 million yuan and launched its first interim dividend of 1.5 yuan per 10 shares. Returning cash signals management confidence and supports the share price.
Capital returns are a direct, ongoing support for the stock and show confidence.
New product is promising but still small versus weak share price The medical aesthetic injectable is a long-term opportunity, but it is new and unproven in sales. The stock has fallen about 15% this year and trades around 30-35 yuan, so the market still waits for proof it can lift overall growth.
This is the honest counterweight: the new product is early-stage and the stock has been weak.